[go: up one dir, main page]

BRPI0914545A2 - compounds and compositions as kinase inhibitors - Google Patents

compounds and compositions as kinase inhibitors

Info

Publication number
BRPI0914545A2
BRPI0914545A2 BRPI0914545A BRPI0914545A BRPI0914545A2 BR PI0914545 A2 BRPI0914545 A2 BR PI0914545A2 BR PI0914545 A BRPI0914545 A BR PI0914545A BR PI0914545 A BRPI0914545 A BR PI0914545A BR PI0914545 A2 BRPI0914545 A2 BR PI0914545A2
Authority
BR
Brazil
Prior art keywords
compositions
compounds
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
BRPI0914545A
Other languages
Portuguese (pt)
Inventor
Chen Bei
Yang Kunyong
Jiang Songchun
H Marsilje Thomas
Lu Wenshuo
He Xiaohui
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Priority claimed from PCT/US2009/048428 external-priority patent/WO2010002655A2/en
Publication of BRPI0914545A2 publication Critical patent/BRPI0914545A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0914545A 2008-06-25 2009-06-24 compounds and compositions as kinase inhibitors BRPI0914545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
PCT/US2009/048428 WO2010002655A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0914545A2 true BRPI0914545A2 (en) 2017-05-23

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914545A BRPI0914545A2 (en) 2008-06-25 2009-06-24 compounds and compositions as kinase inhibitors

Country Status (11)

Country Link
EP (1) EP2331526A2 (en)
JP (1) JP2011526291A (en)
KR (1) KR20110020940A (en)
CN (1) CN102203083A (en)
AU (1) AU2009262198B2 (en)
BR (1) BRPI0914545A2 (en)
CA (1) CA2729546A1 (en)
EA (1) EA201100078A1 (en)
MX (1) MX2010014568A (en)
UA (1) UA101057C2 (en)
WO (1) WO2009158431A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
WO2013079505A1 (en) * 2011-11-29 2013-06-06 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
CN104854101B (en) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk kinase inhibitors
ES2738493T3 (en) * 2013-03-14 2020-01-23 Tolero Pharmaceuticals Inc JAK2 and ALK2 inhibitors and methods for their use
EP3150592B1 (en) * 2014-05-30 2023-08-30 Shanghai Emerald Wellcares Pharmaceutical Co., LTD Alk kinase inhibitor, and preparation method and use thereof
US10377743B2 (en) * 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN107488148A (en) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 A kind of hydrocinnamamide insecticides and preparation method thereof
JP7569688B2 (en) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202045008A (en) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds, preparation and use thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
EP4103182A4 (en) * 2020-02-14 2024-02-21 Salk Institute for Biological Studies ULK1/2 INHIBITORS AND METHODS OF USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
JP4886511B2 (en) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
DE602004032446D1 (en) * 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
US8211929B2 (en) * 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
PL2091918T3 (en) * 2006-12-08 2015-02-27 Novartis Ag Compounds and compositions as protein kinase inhibitors
HRP20141260T1 (en) * 2006-12-08 2015-03-13 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
MX2010008700A (en) * 2008-02-22 2010-08-30 Hoffmann La Roche Modulators for amyloid beta.

Also Published As

Publication number Publication date
AU2009262198B2 (en) 2012-09-27
WO2009158431A3 (en) 2010-03-11
EP2331526A2 (en) 2011-06-15
CA2729546A1 (en) 2009-12-30
EA201100078A1 (en) 2011-08-30
JP2011526291A (en) 2011-10-06
KR20110020940A (en) 2011-03-03
UA101057C2 (en) 2013-02-25
CN102203083A (en) 2011-09-28
WO2009158431A2 (en) 2009-12-30
MX2010014568A (en) 2011-03-29
AU2009262198A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
BRPI0914652A2 (en) compounds and compositions as kinase inhibitors
BRPI0912668A2 (en) compound and compositions as kinase inhibitors
BRPI0906973A2 (en) Compounds and compositions as kinase inhibitors.
BRPI0911228A2 (en) compounds and compositions as protein kinase inhibitors
CY2019027I1 (en) PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
LTPA2019006I1 (en) Compounds and compositions as protein kinase inhibitors
BRPI0910979A2 (en) compounds and compositions as kinase inhibitors
BRPI0920135A2 (en) imidazopyridazinecarbonitriles useful as kinase inhibitors
BRPI0913879A2 (en) phenylpyrazinones as kinase inhibitors
BRPI0908849A2 (en) Compound and compositions as c-kit and pdgfr kinase inhibitors
BRPI0811516A2 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
BRPI0914545A2 (en) compounds and compositions as kinase inhibitors
BR112012004448A2 (en) "compounds and compositions as protein kinase inhibitors"
BRPI0719797A2 (en) compounds and compositions as protein kinase inhibitors
BRPI0912475A8 (en) compounds as kinase inhibitors
BRPI0913580A2 (en) pyrrolopyridines as kinase inhibitors
BRPI0811065A2 (en) 5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS
DK2634232T3 (en) COMPOSITIONS
BRPI0908494A2 (en) Pyrrolopyrazine kinase inhibitors
BRPI0906749A2 (en) Composition
BRPI0913808A2 (en) composition
BRPI0820544A2 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
BRPI0918846A2 (en) heterocyclic kinase inhibitors
EP2381760A4 (en) ZEINE COMPOSITION
ATE519763T1 (en) PYRROLOPYRAZINE KINASE INHIBITORS

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07D 403/14 (2006.01), C07D 401/14 (2006.01), C07D

B350 Update of information on the portal [chapter 15.35 patent gazette]